{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:28:01Z","timestamp":1792898881048,"version":"4.5.0"},"reference-count":26,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    Relapsed\/refractory follicular lymphoma (R\/R FL) remains a clinically challenging condition, with progressively declining benefit across consecutive lines of therapy. While anti\u2010Cluster of Differentiation 20 (CD20) antibodies remain the therapeutic backbone, the optimal targeted or immune\u2010based partner remains undefined. A systematic review and network meta\u2010analysis (NMA) of 5 phase III and 1 phase II trials (2500 patients) evaluated seven anti\u2010CD20\u2010based combination strategies. Primary end\u2010points were overall survival (OS) and progression\u2010free survival (PFS); secondary end\u2010points included objective response rate (ORR) and grade \u22653 adverse events. Treatments were ranked using surface under the cumulative ranking (SUCRA) values. Immune\u2010activating strategies ranked highest across efficacy end\u2010points. Epcoritamab plus rituximab (R\n                    <jats:sup>2<\/jats:sup>\n                    ) achieved the top SUCRA rankings for OS, PFS and ORR, while tafasitamab plus R\n                    <jats:sup>2<\/jats:sup>\n                    consistently ranked second, with a better safety profile. R\n                    <jats:sup>2<\/jats:sup>\n                    alone showed intermediate efficacy and good tolerability, whereas zanubrutinib plus anti\u2010CD20 demonstrated modest efficacy with lower toxicity. Bortezomib and copanlisib\u2010based combinations ranked lowest for efficacy, with phosphoinositide 3\u2010kinase (PI3K) inhibitor\u2013based regimens showing the least favourable benefit\u2013risk profile. Anti\u2010CD20 monotherapy was the safest but least effective option. This NMA indicates that immune\u2010centric, anti\u2010CD20\u2010anchored combinations represent the most effective chemotherapy\u2010free strategies for R\/R FL. Combinations incorporating anti\u2010CD19 or CD20\/CD3 bispecific antibodies appear to offer deeper disease control, particularly in high\u2010risk and rituximab\u2010refractory disease.\n                  <\/jats:p>","DOI":"10.1111\/bjh.70649","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T17:05:38Z","timestamp":1782925538000},"page":"874-886","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical outcomes of the chemo\u2010free approach in relapsed\/refractory follicular lymphoma: A network meta\u2010analysis"],"prefix":"10.1111","volume":"209","author":[{"given":"Daniele","family":"Caracciolo","sequence":"first","affiliation":[{"name":"Department of Experimental and Clinical Medicine (DMSC) Magna Graecia University  Catanzaro Italy"},{"name":"Medical and Translational Medical Oncology Units, and Phase 1 Trial Center in Oncology and Onco\u2010Hematology AOU Renato Dulbecco  Catanzaro Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rita","family":"Lombardo","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine (DMSC) Magna Graecia University  Catanzaro Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Reitano","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine (DMSC) Magna Graecia University  Catanzaro Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Napoli","sequence":"additional","affiliation":[{"name":"Medical and Translational Medical Oncology Units, and Phase 1 Trial Center in Oncology and Onco\u2010Hematology AOU Renato Dulbecco  Catanzaro Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Fiorillo","sequence":"additional","affiliation":[{"name":"Medical and Translational Medical Oncology Units, and Phase 1 Trial Center in Oncology and Onco\u2010Hematology AOU Renato Dulbecco  Catanzaro Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Callerame","sequence":"additional","affiliation":[{"name":"Medical and Translational Medical Oncology Units, and Phase 1 Trial Center in Oncology and Onco\u2010Hematology AOU Renato Dulbecco  Catanzaro Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Garritano","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine (DMSC) Magna Graecia University  Catanzaro Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Bulotta","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine (DMSC) Magna Graecia University  Catanzaro Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha","family":"Munir","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine (DMSC) Magna Graecia University  Catanzaro Italy"},{"name":"Medical and Translational Medical Oncology Units, and Phase 1 Trial Center in Oncology and Onco\u2010Hematology AOU Renato Dulbecco  Catanzaro Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Pensabene","sequence":"additional","affiliation":[{"name":"Medical and Translational Medical Oncology Units, and Phase 1 Trial Center in Oncology and Onco\u2010Hematology AOU Renato Dulbecco  Catanzaro Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiliano","family":"Barbieri","sequence":"additional","affiliation":[{"name":"Hematology Division Azienda Unit\u00e0 Sanitaria Locale Istituto di Ricerca e Cura a Carattere Scientifico of Reggio Emilia  Reggio Emilia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Bavieri","sequence":"additional","affiliation":[{"name":"Doctorate School of Clinical and Experimental Medicine University of Modena and Reggio Emilia  Modena Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierfrancesco","family":"Tassone","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine (DMSC) Magna Graecia University  Catanzaro Italy"},{"name":"Medical and Translational Medical Oncology Units, and Phase 1 Trial Center in Oncology and Onco\u2010Hematology AOU Renato Dulbecco  Catanzaro Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierosandro","family":"Tagliaferri","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine (DMSC) Magna Graecia University  Catanzaro Italy"},{"name":"Medical and Translational Medical Oncology Units, and Phase 1 Trial Center in Oncology and Onco\u2010Hematology AOU Renato Dulbecco  Catanzaro Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Luminari","sequence":"additional","affiliation":[{"name":"Hematology Division Azienda Unit\u00e0 Sanitaria Locale Istituto di Ricerca e Cura a Carattere Scientifico of Reggio Emilia  Reggio Emilia Italy"},{"name":"Department Chimomo University of Modena and Reggio Emilia  Modena Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2020.02.001"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15174403"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00155-6"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70027-0"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70140"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.70126"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1363102"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00010"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00775"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70150-4"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00145-5"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01778-7"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)02360-8"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00591-X"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025454"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01622-0"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-021-00614-8"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.70105"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.18549\/PharmPract.2017.01.943"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-016-1583-7"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-021-01397-5"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDe2600097"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-026-06891-8"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00395-y"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-020-00204-z"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-011258"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.70649","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.70649","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.70649","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:03:26Z","timestamp":1789193006000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.70649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1111\/bjh.70649"],"URL":"https:\/\/doi.org\/10.1111\/bjh.70649","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"2026-03-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}